<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> receptor alpha (RAR alpha) protein plays a central role in myeloid differentiation, and chromosomal translocations disrupting the RAR alpha gene are implicated in the development of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>To identify haemopoietic malignant disorders which may also be linked to RAR alpha abnormalities, Southern blot analysis was performed in DNA from 153 patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> other than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> FAB type M3 using RAR alpha cDNA probes </plain></SENT>
<SENT sid="2" pm="."><plain>Alterations of RAR alpha were detected in 1/42 <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), 2/24 AML, 3/47 B-<z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemias</z:mpath> (B-CLL), 0/40 <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and 0/60 <z:mpath ids='MPATH_458'>normal</z:mpath> individuals </plain></SENT>
<SENT sid="3" pm="."><plain>These data strongly suggest that alterations of RAR alpha might predispose for myeloid and lymphoid disorders </plain></SENT>
</text></document>